New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:38 EDTENTAEnanta Pharmaceuticals ABT-493 has potential, says JMP Securities
After examining data on Enanta's protease inhibitor, ABT-493. JMP Securities is encouraged by the drug's potential, as the firm thinks it can be competitive in the HCV space. The firm reiterates a $50 price target and Outperform rating on the shares.
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
17:33 EDTENTAS&P announces changes to S&P 400, 500, and 600 indices
Subscribe for More Information
17:19 EDTENTAEnanta to replace PAREXEL in S&P 600 as of 7/28 close
14:56 EDTENTAEnanta announces FDA approval of AbbVie's Technivie
Enanta Pharmaceuticals (ENTA) announced that the FDA approved AbbVie’s (ABBV) Technivie -- ombitasvir, paritaprevir and ritonavir -- tablets in combination with ribavirin for the treatment of non-cirrhotic adults with genotype 4 chronic hepatitis C virus, or HCV, infection. Technivie is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. Paritaprevir is Enanta’s lead protease inhibitor identified within the ongoing Enanta-AbbVie collaboration and is one of the two direct-acting antivirals (2-DAA) in AbbVie’s Technivie.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use